monopolar spindle 1

BAY 1217389 is an effective and selective inhibitor of the monopolar spindle 1 (MPS1) kinase (IC50<10 nM).

NMS-P715 is a selective and ATP-competitive MPS1 inhibitor(IC50 of 182 nM).

BOS-172722 is an inhibitor of the monopolar spindle 1 (MPS1) checkpoint with an IC50 of 2 nM.

Mps1-IN-3 is an effective and selective inhibitor of MPS1 kinase (IC50: 50 nM).

Mps1-IN-2 is a potent, selective, and ATP-competitive inhibitor of both Mps1 and Plk1.

MPI-0479605 is an ATP competitive and selective inhibitor.

AZ3146 is a selective Mps1 inhibitor with IC50 of ~35 nM.

Empesertib (BAY 1161909) is an orally bioavailable and selective inhibitor Mps1(IC50 < 1 nM), with potential antineoplastic activity.

CCT251455, the mitotic kinase monopolar spindle 1 (MPS1/TTK) inhibitor, is a potent (IC50=3 nM) and specific chemical tool.

TC-Mps1-12 is an effective and selective inhibitor of monopolar spindle 1 (IC50: 6.4 nM) .

PROTAC MPS1 Degrader 2 (Compound 15) is a potent degrader of monopolar spindle 1 (Mps1, TTK), AURKA, and AURKB with DC50 values of 42.0, 2.1, and 154.0 nM respectively. It is utilized in the research of acute myeloid leukemia.

PROTAC MPS1 degrader 1 (Compound 19) acts as a potent degrader of Monopolar spindle 1 (Mps1, TTK), AURKA, and AURKB, with DC50 values of 17.7, 108.7, and 570.3 nM respectively. It is utilized in the study of acute myeloid leukemia. (Pink: ligand for target protein; Black: linker; Blue: ligand for E3 ligase)

CFI-402257 (Luvixasertib) is a highly selective oral TTK (Mps1, Monopolar Spindle 1) kinase inhibitor that potently inhibits TTK kinase activity (Mps1 Ki = 0.09 nM；EC50 = 6.5 nM). It is intended for use in research on hepatocellular carcinoma and breast cancer.

MPS1/TTK inhibitor is an inhibitor of monopolar spindle 1 (MPS1/TTK; IC50 = 5.8 nM), a kinase involved in mitotic spindle checkpoint signaling that is overexpressed in certain cancerous tumors. It inhibits MPS1 phosphorylation of kinetochore scaffold 1 (KNL1) and increases the rate of mitosis and the number of cells entering anaphase within 15 minutes, indicating MPS1 checkpoint inhibition, when used at a concentration of 100 nM. MPS1/TTK inhibitor (50 and 100 nM) increases the number of missegregated chromosomes, with an increased number of errors at 100 nM compared with 50 nM. It also inhibits colony formation of DLD1, HCT116, and U2OS cells (IC50s = 24.6, 20.1, and 20.6 nM, respectively).

Mps1-IN-4 is a compound that selectively inhibits Monopolar spindle 1 (Mps1), exhibiting antiproliferative properties useful in cancer research.

RMS-07, a covalent inhibitor of Monopolar Spindle Kinase 1 (MPS1/TTK), exhibits a potent inhibitory concentration (IC50) of 13.1 nM. Specifically, it targets a poorly conserved cysteine located in the hinge region of the kinase.